Webinar: From Lab to NewCo — IP Spinouts in Life Sciences

When a promising asset sits inside a pharma portfolio or breakthrough IP emerges from a university lab, how does it transform into a standalone company—and what do the deal terms, equity structures, and regulatory hurdles look like?

Join Ryan McRobert, Robert Slack, and Feihong Xu for a practical exploration of life sciences IP spinouts.

Key Topics Covered:

• Corporate Spinouts: Motivations for spinning out portfolio assets, and how equity, licensing, and fundraising are structured.
• University Spinouts: Strategies for working with technology transfer offices (TTOs), negotiating license terms, and managing founder conflicts.
• Regulatory Considerations: Navigating CFIUS and national security regulations in cross-border transactions.